| Identification | Back Directory | [Name]
MCC950 | [CAS]
210826-40-7 | [Synonyms]
MCC950
CS-2292
CP-456773
MCC950
(MCC-950
1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(2-hydroxypropan-2-yl)furan-2-yl]sulfonylurea
N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamid
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide
N-[[(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide
2-Furansulfonamide, N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)- | [EINECS(EC#)]
604-604-1 | [Molecular Formula]
C20H24N2O5S | [MDL Number]
MFCD28900720 | [MOL File]
210826-40-7.mol | [Molecular Weight]
404.48 |
| Chemical Properties | Back Directory | [Melting point ]
239 °C | [density ]
1.396±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
Soluble in DMSO (up to 40 mg/ml) or in Water (up to 30 mg/ml) | [form ]
solid | [pka]
4.74±0.10(Predicted) | [color ]
White | [Stability:]
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20°C for up to 1 month. |
| Hazard Information | Back Directory | [Description]
MCC-950 (210826-40-7) was originally found to act as a cytokine release inhibitory drug (CRID), arresting activated monocytes and preventing activation of caspase-1.1?Discovered to be a novel inhibitor of the NLRP3 and AIM2 inflammasomes.2?MCC-950 blocks canonical and noncanonical NLRP3 activation at nanomolar concentrations.3?Inhibits interleukin 1β (IL-1β) secretion?in vivo?and attenuates the severity of experimental autoimmune encephalomyelitis (an MS disease model).3?Disrupts the interaction between AIM2 and ASC in a reconstituted cell-free inflammasome.4?MCC-950 is a valuable new tool for exploring the pathophysiology of NLRP3. | [Uses]
MCC950 selectively inhibits pyrin domain-containing protein 3 (NLRP3) inflammasome, a protein complex involved in the inflammatory process (1). The NLRP3 inflammasome is related to a wide range of immune disorders such as multiple sclerosis, inflammatory bowel disease, auto-immune and auto-inflammatory diseases (2). MCC950 has been shown to specifically inhibit the activation of NLRP3 but not the AIM2, NLRC4 or NLRP1 inflammasomes (1). MCC950 is a potential therapeutic for NLRP3-associated syndromes. | [in vivo]
MCC950 reduces Interleukin-1p (IL-1β) production and attenuates the severity of experimental autoimmune encephalomyelitis (EAE), a disease model of multiple sclerosis. Pre-treatment with MCC950 reduces serum concentrations of IL-1β and IL-6 while it does not considerably decrease the amount of TNF-α. Treatment of mice with MCC950 delays the onset and reduced the severity of EAE. Intracellular cytokine staining and FACS analysis of brain mononuclear cells from mice sacrificed on day 22 shows modestly reduced frequencies of IL-17 and IFN-γ producing CD3+ T cells in MCC950 treated mice in comparison with PBS-treated mice. IFN-γ and particularly IL-17 producing cell numbers are also reduced in both the CD4+ and γδ+ sub-populations of CD3+ T cells[1]. | [IC 50]
NLRP3 | [References]
1) Laliberte?et al.?(2003),?Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing; J. Biol. Chem.,?278?16567
2) Coll?et al. (2011),?The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes; Clin. PLoS One,?6(12)?e29539
3) Coll?et al.?(2015),?A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory disease; Nat. Med.,?21?248
4) Kaneko?et al.?(2015),?Reconstituted AIM2 inflammasome in cell-free system; J. Immunol. Methods,?426?76 |
|
|